Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Curr Drug Metab. 2010 Oct;11(8):693–714. doi: 10.2174/138920010794233477

Table 4.

Potential Negative Practices and Suggested Beneficial Approaches for MHT in Postmenopausal CVD.

Potentially Negative Potentially Beneficial
MHT using CEE MHT using 17β-estradiol
Oral administration of MHT Transdermal administration of MHT
Beginning of MHT late after menopause Beginning of MHT early after menopause
High dose of MHT Low dose of MHT
Progestins with adverse effects (MPA) Cyclic administration of MHT
Drospirenone Administration
HHS Vulnerability Disclosure